Resumo

COSTA GIL, José E et al. Eficacia y seguridad de IdegLira para la intensificación del tratamiento en la diabetes tipo 2. Medicina (B. Aires) [online]. 2018, vol.78, n.4, pp.225-233. ISSN 0025-7680.

Diabetes mellitus is a true pandemic; type 2 diabetes in particular, with its progressive nature, constitutes a serious health problem. Despite advances and innovations in treatment, it continues to generate high morbidity and mortality.Many patients do not achieve their metabolic control objectives, due to clinical inertia, fear of hypoglycaemia, weight gain, the complexity of the treatment and the lack of adherence to it. Recently, the clinical results of the combined use of basal insulin and agonist receptor of the glucagon-like peptide type 1 (AR-GLP1) have been successfully evaluated. Therefore, the combined use of a basal insulin (insulin degludec) with an AR-GLP1 (liraglutide), in a single device (IdegLira), is proposed as an effective and safe therapeutic alternative for the treatment intensification in people with type 2 diabetes. IdegLira has shown greater reductions in HbA1c compared to its individual components, with a low risk of hypoglycaemia and weight loss, both in insulin naïve patients and in those previously insulinized. In this review we describe the pharmacology, the rational of the combination and the most relevant clinical evidence on IdegLira safety and efficacy.

Palavras-chave : IDegLira; Insulin degludec; Liraglutide; Type 2 diabetes.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )